| EPB0198 | A patient with undiagnosed HIV presenting with hemophagocytic lymphohistiocytosis - the importance of routine HIV testing in hospitalized patients | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPB0199 | Weight gain and lipid changes with switching from boosted protease inhibitor-based regimens to bictegravir/tenofovir alafenamide/emtricitabine | E-poster | Clinical complications of HIV and antiretroviral therapy |
| LBEPB12 | Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks | E-poster | Clinical complications of HIV and antiretroviral therapy |
| LBPEB01 | Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study | Poster exhibition | Clinical complications of HIV and antiretroviral therapy |
| MOPEB17 | Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75mg) once-daily: week 48 results from 2 randomized, active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Poster exhibition | Clinical complications of HIV and antiretroviral therapy |
| MOPEB18 | A randomized controlled trial of (5R)-5-hydroxytriptolide in HIV INRs receiving ART | Poster exhibition | Clinical complications of HIV and antiretroviral therapy |
| MOPEB19 | Weight gain among people living with HIV in Zambia transitioning to dolutegravir-based antiretroviral regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate | Poster exhibition | Clinical complications of HIV and antiretroviral therapy |
| OAB0203 | Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OALBB0502 | A prospective, randomized trial to assess a protease inhibitor–based regimen switch strategy to manage integrase inhibitor–related weight gain | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OALBB0504 | Risks of hypertension with first-line dolutegravir (DTG) and tenofovir alafenamide (TAF) in the NAMSAL and ADVANCE trials | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |